Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Pi-Li Hu"'
Autor:
Lin-Quan Tang, Xiao-Yun Li, Zhi-Ming Li, Zhi-Gang Liu, Miao-Zhen Lin, Huan Zhou, Qi-Wen Yu, Jian Zhou, Chong Zhao, Ze-Bin Chen, Xi-Cheng Wang, Jia-Yu Peng, Qiu-Yan Chen, Wen-Feng Fang, Yun-Peng Yang, Bei Zhang, Liang-Ping Xia, Pi-Li Hu, Wei-Han Hu, Yi-Jie Li, Hai-Qiang Mai, Xiu-Yu Cai
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background Previous studies have shown that monotherapy with apatinib, an oral tyrosine kinase inhibitor, has promising efficacy for treating recurrent or metastatic (RM) nasopharyngeal carcinoma (NPC) patients. In this study, we aimed to as
Externí odkaz:
https://doaj.org/article/d39243ce9eed47f6b32e467b391849f8
Autor:
Fang Wang, Gui-fang Guo, Hui-juan Qiu, Wen-zhuo He, Fei-fei Zhou, Xu-xian Chen, Pi-li Hu, Bei Zhang, Chen-xi Yin, Li Zhang, Liang-ping Xia
Publikováno v:
Cancer Biology & Medicine, Vol 9, Iss 1, Pp 38-43 (2012)
Objective The standard therapy after failure of the initial non-first line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in advanced non-small cell lung cancer (NSCLC) has not yet been established. The aim of the cur
Externí odkaz:
https://doaj.org/article/f4e36b10ce6a4ab6b437f7ecd47c1338
Autor:
Fang, Wang, Gui-Fang, Guo, Hui-Juan, Qiu, Wen-Zhuo, He, Fei-Fei, Zhou, Xu-Xian, Chen, Pi-Li, Hu, Bei, Zhang, Chen-Xi, Yin, Li, Zhang, Liang-Ping, Xia
Publikováno v:
Cancer Biology & Medicine
Objective The standard therapy after failure of the initial non-first line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in advanced non-small cell lung cancer (NSCLC) has not yet been established. The aim of the cur
Autor:
Pi Li Hu, Fei Fei Zhou, Xu Xian Chen, Li Zhang, Fang Wang, Liang Ping Xia, Bei Zhang, Gui Fang Guo, Hui Juan Qiu, Wen Zhuo He
Publikováno v:
Medical oncology (Northwood, London, England). 28
Cetuximab combined with chemotherapy has been used to treat Non-small cell lung cancer (NSCLC) in recent years, however, the data from China was rare. This study was to summarize our experiences in treating NSCLC patients with cetuximab in the first
Autor:
Feifei Zhou, Mao-Zhen Liu, Yuming Rong, Liangping Xia, Pi-Li Hu, Bei Zhang, Huijuan Qiu, Sui-Yi Qian, Yuanyuan Huang, Tao-Li Wang, Guifang Guo, Xuxian Chen
Publikováno v:
Ai zheng = Aizheng = Chinese journal of cancer. 28(9)
Background and objective Cetuximab combined with radiotherapy or chemotherapy has been used to treat head and neck cancer in recent years, but few reports are available in China now. This study was to summarize our experiences in treating patients wi
Publikováno v:
Ai zheng = Aizheng = Chinese journal of cancer. 23
The majority of cancer chemotherapy can lead to bone marrow depression, which often affects clinical response as chemotherapy can not be carried out with enough dosage on time. The platelets decrease is one of the problems caused by bone marrow depre
Autor:
Guo-Xian, Huang, Chong, Zhao, Fei, Han, Bei, Zhang, Hui-Juan, Qiu, Bo-Ping, Xu, Xu-Xian, Chen, Pi-Li, Hu
Publikováno v:
Ai zheng = Aizheng = Chinese journal of cancer. 22(10)
Oropharyngeal mucositis is the most common acute non-hematology toxicity in nasopharyngeal carcinoma (NPC) treated with radiotherapy, especially in the concomitant chemoradiotherapy of local advanced NPC patients. This study was designed to observe t
Autor:
Ning-Ning, Zhou, Zhong-Mei, Zhou, Mao-Zhen, Liu, Yu-Hong, Li, Rui-Hua, Xu, Xiao-Yu, Teng, Xiao-Juan, Xiang, Wei-Hua, Tian, Dong-Geng, Liu, Pi-Li, Hu, Bei, Zhang, Hui-Juan, Qiu, Sui-Yi, Qian, You-Jian, He
Publikováno v:
Ai zheng = Aizheng = Chinese journal of cancer. 22(8)
Phase II clinical trails showed that paclitaxel is effective in treatment of advanced gastric cancer (AGC). The combination of paclitaxel and 5-fluorouracil (5-FU) in the treatment of advanced gastric cancer is effective and safe. This study was desi